1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCancer Prevention & Research Institute of Texas (CPRIT) Company Commercialization Awards is sponsored by Cancer Prevention & Research Institute of Texas (CPRIT). This opportunity supports mission-aligned projects and measurable outcomes.
Get alerted about grants like this
Save a search for “Cancer Prevention & Research Institute of Texas (CPRIT)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Welcome to the Cancer Prevention and Research Institute of Texas Application Receipt System I am a returning CPRIT Application Receipt System user I am a new CPRIT Application Receipt System user Please be advised that the RRCTA RFA and IFA documents have been updated to clarify eligibility requirements and review criteria. Please be advised that the REI, RFT, and RRS RFA and IFA documents for FY2026 Academic Research have been updated.
View the RFA Release and Peer Review Schedule . CPRIT now supports ORCID ID's in Applicant Profiles.
AWARD MECHANISMS ACCEPTING APPLICATIONS: Recruitment or Retention of Clinical Trialists Award (RRCTA) Application receipt period: September 9, 2025 - May 20, 2026 Recruitment of First-Time, Tenure - Track Faculty Members (RFT) Recruitment of Rising Stars (RRS) Recruitment of Established Investigators (REI) Application receipt period: June 23, 2025 - June 22, 2026 Cancer Screening and Early Detection (CSD) Primary Prevention of Cancer (PPC) Dissemination of CPRIT-Funded Cancer Control Interventions (DI) Application receipt period: March 18, 2026 - June 10, 2026 Product Development Research Texas Therapeutics Company Awards for Product Development Research (TTC) Texas Diagnostic and Devices Company Awards for Product Development Research (TDDC) Texas New Technologies Company Awards for Product Development Research (TNTC) SEED Awards for Product Development Research (SEED) Application receipt period: Preliminary Applications: April 7, 2026 - April 16, 2026 Full Application Receipt Closing Date: July 9, 2026 View our Statute, Rules and Grant Policies Guide .
CPRIT's guidance to define prevention research and prevention non-research is available here (5/10/12). CGMS Grantee Training slide presentation available . Data Classification Policy v1.
5. 0. pdf Frequently Asked Questions Call or email our HelpDesk Download agreement documents: Electronic User Agreement Tobacco-free Workplace Policy Certification Tobacco-free Workplace Policy Certification Waiver Grantee Resources, Forms and Guidance Documents This is a Cancer Prevention and Research Institute of Texas computer system, which may be accessed and used only for official Government business by authorized personnel.
Unauthorized access or use of this computer system may subject violators to criminal, civil, and/or administrative action. Any information on this computer system may be intercepted, recorded, read, copied, and disclosed by and to authorized personnel for official purposes, including criminal investigations. Access or use of this computer system by any person whether authorized or unauthorized, constitutes consent to these terms.
Contact the CPRIT Application Receipt System Helpdesk
Based on current listing details, eligibility includes: For-profit companies based in Texas working in cancer research, product development, and prevention. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $500,000–$2,000,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.